Last Update 20 May 26

Fair value Decreased 0.45%

EYPT: Phase 3 Eye Disease Program Will Drive Future Upside Potential

Narrative Update on EyePoint

Analysts have adjusted the average price target on EyePoint to $37.00 from $37.17. This change reflects recent upward target revisions into the $29 to $35 range as they consider updated Q4 results, progress on Duravyu programs, and the inclusion of the Phase 3 diabetic macular edema program in their valuation work.

Analyst Commentary

Recent research commentary on EyePoint centers on refreshed valuation work after Q4 results, updates on Duravyu programs, and the explicit inclusion of the Phase 3 diabetic macular edema program in some models. The changes in price targets into the high 20s and low to mid 30s provide context for how analysts are thinking about risk and potential execution ahead.

Bullish Takeaways

Bullish analysts are factoring the Phase 3 diabetic macular edema program directly into their valuation frameworks, which supports higher price targets in the US$29 to US$35 range.
Updates around Duravyu programs following Q4 results are being incorporated into models, and bullish analysts view this pipeline work as a key part of the stock's appeal.
The clustering of recent price targets between US$29 and US$35 indicates that some analysts see room for execution on current programs relative to prior expectations.
Following Q4, bullish analysts appear comfortable refining their estimates rather than pulling back, which reflects confidence in the information the company has provided on its programs.

Bearish Takeaways

Even with higher targets, the price ranges cited by analysts still indicate execution risk around the Phase 3 diabetic macular edema program, since outcomes and timelines are not yet known.
Analysts updating models after Q4 results and Duravyu updates are relying on assumptions about future development progress, which can be a source of forecast error if programs are delayed or revised.
The spread between the lower and upper ends of recent price targets, from US$29 to US$35, highlights differing views on how much value to assign to current clinical programs.
With price targets concentrated in a relatively tight band, some investors may question how much upside is being modeled relative to the risks that typically come with late stage clinical development.

What’s in the News

The independent Data Safety Monitoring Committee completed its third scheduled review of EyePoint’s pivotal Phase 3 DURAVYU program for wet age related macular degeneration and recommended that the LUGANO and LUCIA trials continue as planned with no protocol changes, with all active patients in the treatment arm reaching the Week 32 second dose and over 35% reaching the Week 56 third dose (Key Developments).
Interim masked safety data from the LUGANO and LUCIA Phase 3 trials indicate a continued favorable safety profile for DURAVYU, consistent with safety reported in over 190 patients across four completed trials, with no drug related safety concerns reported in those completed studies (Key Developments).
Enrollment in the LUGANO and LUCIA trials is complete, with over 900 wet AMD patients randomized to either DURAVYU 2.7 mg every six months or on label aflibercept, using a non inferiority design based on average change in best corrected visual acuity at weeks 52 and 56 (Key Developments).
EyePoint dosed the first patient in each of the Phase 3 COMO and CAPRI global trials of DURAVYU for diabetic macular edema, with roughly 240 patients planned per trial, comparing 6 month DURAVYU dosing with on label aflibercept control (Key Developments).
The DURAVYU DME Phase 3 program, informed by a positive End of Phase 2 FDA meeting and aligned with both FDA and EMA, uses non inferiority visual acuity endpoints and tracks secondary measures such as treatment burden and anatomical outcomes on optical coherence tomography (Key Developments).

Valuation Changes

Fair Value: The modeled fair value has edged lower from $37.17 to $37.00, reflecting a small downward adjustment.
Discount Rate: The discount rate has risen slightly from 6.98% to 7.11%, implying a modestly higher required return in the updated work.
Revenue Growth: The assumed revenue growth rate has increased from 102.60% to about 2.5x, indicating a much steeper projected ramp in dollar revenue.
Net Profit Margin: The projected profit margin has softened slightly, easing from 18.87% to 18.15% in the latest model.
Future P/E: The future P/E multiple has been reduced from 94.28x to 76.48x, pointing to a lower valuation multiple being applied in the updated assumptions.

0 views

Key Takeaways

Successful late-stage trials and a durable eye disease treatment position the company for strong physician adoption and significant revenue growth upon approval.
Strategic expansion, robust manufacturing, and disciplined financial management lower risk and enable long-term pipeline and market opportunity development.
Heavy dependence on DURAVYU, combined with declining revenue, escalating costs, and industry and execution risks, threatens financial stability and future market competitiveness.

Catalysts

About EyePoint Pharmaceuticals

Engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.What are the underlying business or industry changes driving this perspective?

Accelerated completion and strong execution of pivotal Phase III trials for DURAVYU in wet-AMD, targeting a large and expanding population of elderly patients with retinal disease, positions EyePoint for potential first-to-market advantage-expected to drive substantial topline revenue growth.
Demonstrated robust efficacy, long-acting dosing (every 6 months), and favorable safety profile of DURAVYU addresses the physician and patient demand for more durable ocular therapies, supporting physician adoption and expanding the addressable market, with likely positive impact on revenue and margins post-approval.
Expansion into diabetic macular edema (DME), underpinned by positive Phase II results and a growing diabetic population worldwide, introduces significant pipeline diversification and potential for long-term revenue streams.
Investment in state-of-the-art, scalable cGMP manufacturing capacity and disciplined cash management (cash runway into 2027) reduces operational risk, lowering the likelihood of further dilution and preserving future earnings and net margins as commercial sales ramp.
Early commercial planning, strong engagement with retinal specialists, and global trial expansion establish relationships and infrastructure to support rapid and broad market adoption, enhancing both future revenue trajectory and operating leverage.

EyePoint Pharmaceuticals Earnings and Revenue Growth

EyePoint Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming EyePoint's revenue will grow by 252.7% annually over the next 3 years.
Analysts are not forecasting that EyePoint will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate EyePoint's profit margin will increase from -3567.1% to the average AU Pharmaceuticals industry of 18.2% in 3 years.
If EyePoint's profit margin were to converge on the industry average, you could expect earnings to reach $60.6 million (and earnings per share of $0.59) by about May 2029, up from -$271.6 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $72.1 million in earnings, and the most bearish expecting $-570.3 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 77.0x on those 2029 earnings, up from -3.6x today. This future PE is greater than the current PE for the AU Pharmaceuticals industry at 14.9x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

EyePoint's current net revenue has sharply declined following its exit from the specialty pharma business (from $9.5M to $5.3M year over year), and future revenue is expected to be de minimis until DURAVYU is potentially approved, heightening the risk that delays or setbacks in development or approval could lead to significant periods with minimal or no revenue, thus negatively impacting cash flow and financial stability.
The company remains heavily reliant on its single lead asset, DURAVYU, and given the high operating expenses ($67.6M this quarter, up from $44M year-over-year) and ongoing net losses ($59.4M this quarter), failure to achieve timely regulatory approval or commercial success for DURAVYU could lead to protracted net losses, forced cost-cutting, or shareholder dilution through additional financing.
While EyePoint projects a first-mover advantage in sustained-release wet-AMD therapies, the $10B wet-AMD and $3B DME markets are attracting intense competition; larger or better capitalized competitors, new entrants, and alternative drug delivery technologies could erode DURAVYU's market share, limit pricing power, and keep long-term revenue and margin growth below expectations.
Healthcare industry trends toward stricter drug pricing controls, value-based reimbursement models, and increasing preference for generics or biosimilars could limit DURAVYU's pricing potential, slow adoption, or increase barriers to market access, reducing both revenue growth and net margins over time.
The transition to a pure clinical-stage model and anticipated commercialization build-out introduces execution risk, including potential delays in regulatory approval, manufacturing scale-up, and commercial launch-any missteps in manufacturing, regulatory filings, or early commercialization (especially given the large fixed investment in facilities and organizational expansion) could compress margins, delay earnings improvement, or require further capital raises.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $37.0 for EyePoint based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $68.0, and the most bearish reporting a price target of just $20.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $334.0 million, earnings will come to $60.6 million, and it would be trading on a PE ratio of 77.0x, assuming you use a discount rate of 7.1%.
Given the current share price of $11.82, the analyst price target of $37.0 is 68.1% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on EyePoint?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Phase III Trials In Wet AMD Will Expand Market Reach